Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04013672
Title Phase II Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Manmeet Ahluwalia, MD
Indications

glioblastoma

gliosarcoma

Therapies

Montanide ISA 51 + Pembrolizumab + Sargramostim + SurVaxM

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.